把三张表、经营指标、SEC / 巨潮 / 港交所原始财报、业绩材料和电话会放到同一条可核验时间线上。 披露事实、结构化补位值与派生指标分开标注，缺失逐字稿不会用摘要或模型生成内容补齐。
单季、累计、年度和资产负债表时点分开保存；每个数值都保留单位、申报日、表单、XBRL 概念或原始中文字段。
美股链接 SEC 法定申报和发行人 IR，A 股链接巨潮原始 PDF，港股链接港交所披露易原始年报与中报。分部、订单、产能和客户集中度只在有可核验披露时展示。
官方电话会入口与已授权逐字稿分开。没有合法取得的全文时只显示材料可用性，不生成或拼接虚假的逐字稿。
三张表会执行资产负债、毛利润、税前利润等勾稽检查；超出容差的记录保留原值并标记警告， 不会为了让公式“对上”而修改公司披露。
| 2026-06-30 |
| 3/3 |
| $17.16B |
| $2.17B |
| $7.31B |
| 57.7% |
| — |
| 126 |
| 尚无授权文本 |
| IONS IONIS PHARMACEUTICALS INC | 2026-06-30 | 3/3 | $267.95M | -$114.65M | -$265.13M | 99.0% | -38.2% | 120 | 尚无授权文本 |
| MDGL MADRIGAL PHARMACEUTICALS, INC. | 2026-06-30 | 3/3 | $364.25M | -$57.94M | -$152.21M | — | -15.5% | 87 | 尚无授权文本 |
| PHAT Phathom Pharmaceuticals, Inc. | 2026-06-30 | 3/3 | $74.27M | -$17.58M | -$17.68M | 79.7% | -5.3% | 113 | 尚无授权文本 |
| REGN REGENERON PHARMACEUTICALS, INC. | 2026-06-30 | 3/3 | $4.29B | $1.3B | — | — | 30.1% | 82 | 尚无授权文本 |
| TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD | 2026-06-30 | 3/3 | $4.14B | -$576M | — | 52.0% | -5.6% | 84 | 尚无授权文本 |
| WST WEST PHARMACEUTICAL SERVICES INC | 2026-06-30 | 3/3 | $872.3M | $154M | $128M | 37.7% | 20.5% | 77 | 尚无授权文本 |
| M Macy's, Inc. | 2026-05-02 | 3/3 | $4.68B | $63M | $204M | 38.9% | 2.4% | 103 | 尚无授权文本 |
| FMAC Future Money Acquisition Corp | 2026-04-30 | 3/3 | — | $290,108 | — | — | — | 4 | 尚无授权文本 |
| FMACU Future Money Acquisition Corp | 2026-04-30 | 3/3 | — | $290,108 | — | — | — | 4 | 尚无授权文本 |
| PMCB PharmaCyte Biotech, Inc. | 2026-04-30 | 3/3 | $0 | -$19.42M | — | — | — | 70 | 尚无授权文本 |
| TITN Titan Machinery Inc. | 2026-04-30 | 3/3 | $522.38M | -$12.62M | — | 17.1% | -1.1% | 65 | 尚无授权文本 |
| MTSI MACOM Technology Solutions Holdings, Inc. | 2026-04-03 | 3/3 | $288.96M | $46.33M | $95.46M | 56.9% | 17.6% | 69 | 尚无授权文本 |
| ABOS Acumen Pharmaceuticals, Inc. | 2026-03-31 | 3/3 | — | -$20.74M | — | — | — | 72 | 尚无授权文本 |
| ACAD ACADIA PHARMACEUTICALS INC | 2026-03-31 | 3/3 | $268.06M | $3.64M | $28.77M | 90.8% | -1.7% | 83 | 尚无授权文本 |
| ACXP Acurx Pharmaceuticals, Inc. | 2026-03-31 | 3/3 | — | -$1.68M | — | — | — | 56 | 尚无授权文本 |
| ADIL ADIAL PHARMACEUTICALS, INC. | 2026-03-31 | 3/3 | — | -$2.02M | — | — | — | 144 | 尚无授权文本 |
| AMLX Amylyx Pharmaceuticals, Inc. | 2026-03-31 | 3/3 | — | -$41.28M | — | — | — | 68 | 尚无授权文本 |
| AMPH Amphastar Pharmaceuticals, Inc. | 2026-03-31 | 3/3 | $171.17M | $6.42M | $38.33M | 41.1% | 8.0% | 81 | 尚无授权文本 |
| AMRX Amneal Pharmaceuticals, Inc. | 2026-03-31 | 3/3 | $722.52M | $62.26M | -$34.92M | 44.3% | 19.6% | 87 | 尚无授权文本 |
| ANIP ANI PHARMACEUTICALS INC | 2026-03-31 | 3/3 | $237.46M | $29.49M | $52.3M | — | 16.4% | 115 | 尚无授权文本 |
| APUS Apimeds Pharmaceuticals US, Inc. | 2026-03-31 | 3/3 | — | -$35.06M | -$2.08M | — | — | 24 | 尚无授权文本 |
| ARMP Armata Pharmaceuticals, Inc. | 2026-03-31 | 3/3 | — | -$115.35M | -$5.85M | — | — | 97 | 尚无授权文本 |
| ARWR ARROWHEAD PHARMACEUTICALS, INC. | 2026-03-31 | 3/3 | $73.74M | -$132.73M | $93.21M | — | -191.6% | 86 | 尚无授权文本 |
| ATNM Actinium Pharmaceuticals, Inc. | 2026-03-31 | 3/3 | — | -$5.52M | -$5.87M | — | — | 46 | 尚无授权文本 |
| AUPH Aurinia Pharmaceuticals Inc. | 2026-03-31 | 3/3 | $77.71M | $34.36M | — | 91.6% | 53.3% | 91 | 尚无授权文本 |
| AVIR Atea Pharmaceuticals, Inc. | 2026-03-31 | 3/3 | — | -$45.44M | — | — | — | 63 | 尚无授权文本 |
| BCRX BIOCRYST PHARMACEUTICALS INC | 2026-03-31 | 3/3 | — | -$721.81M | — | — | — | 132 | 尚无授权文本 |
| BMRN BIOMARIN PHARMACEUTICAL INC | 2026-03-31 | 3/3 | $766.21M | $105.53M | $199.73M | 74.6% | 16.9% | 91 | 尚无授权文本 |
| CNSP CNS Pharmaceuticals, Inc. | 2026-03-31 | 3/3 | — | -$4.94M | -$4.65M | — | — | 108 | 尚无授权文本 |
| COLL COLLEGIUM PHARMACEUTICAL, INC | 2026-03-31 | 3/3 | $193.52M | $14.5M | $56.84M | 60.6% | 16.0% | 94 | 尚无授权文本 |
| CPIX CUMBERLAND PHARMACEUTICALS INC | 2026-03-31 | 3/3 | $9.13M | -$3.29M | $387,025 | 78.8% | -34.3% | 98 | 尚无授权文本 |
| CRBP Corbus Pharmaceuticals Holdings, Inc. | 2026-03-31 | 3/3 | — | -$22.97M | -$25.58M | — | — | 118 | 尚无授权文本 |
| CRNX Crinetics Pharmaceuticals, Inc. | 2026-03-31 | 3/3 | $10.73M | -$127.85M | -$125.52M | 98.1% | -1307.8% | 122 | 尚无授权文本 |
| CRVS Corvus Pharmaceuticals, Inc. | 2026-03-31 | 3/3 | — | -$13.69M | -$10.47M | — | — | 87 | 尚无授权文本 |
| CTXR Citius Pharmaceuticals, Inc. | 2026-03-31 | 3/3 | $1.67M | -$28.11M | — | 80.3% | -1931.0% | 137 | 尚无授权文本 |
| CURX Curanex Pharmaceuticals Inc | 2026-03-31 | 3/3 | — | -$3.15M | — | — | — | 14 | 尚无授权文本 |
| CVR CHICAGO RIVET & MACHINE CO | 2026-03-31 | 3/3 | $6.85M | -$362,015 | — | 14.0% | -5.6% | 43 | 尚无授权文本 |
| DMAC DiaMedica Therapeutics Inc. | 2026-03-31 | 3/3 | — | -$10.04M | -$9.09M | — | — | 84 | 尚无授权文本 |
| ELDN Eledon Pharmaceuticals, Inc. | 2026-03-31 | 3/3 | — | -$39.03M | — | — | — | 84 | 尚无授权文本 |
| ELOX Eloxx Pharmaceuticals, Inc. | 2026-03-31 | 3/3 | — | -$3.75M | — | — | — | 81 | 尚无授权文本 |
| ENTA ENANTA PHARMACEUTICALS INC | 2026-03-31 | 3/3 | $17.16M | -$13.09M | -$19.01M | — | -69.1% | 76 | 尚无授权文本 |
| ETON Eton Pharmaceuticals, Inc. | 2026-03-31 | 3/3 | $24.27M | $1.55M | $7.33M | 60.7% | 9.9% | 137 | 尚无授权文本 |
| FENC FENNEC PHARMACEUTICALS INC. | 2026-03-31 | 3/3 | $15.11M | $201,000 | — | — | -0.8% | 80 | 尚无授权文本 |
| FUSE Fusemachines Inc. | 2026-03-31 | 3/3 | $1.88M | -$872,000 | -$2.24M | 50.5% | -161.5% | 17 | 尚无授权文本 |
| GRDN Guardian Pharmacy Services, Inc. | 2026-03-31 | 3/3 | $336.6M | $13.3M | — | 22.7% | 5.3% | 29 | 尚无授权文本 |
| HUMA Humacyte, Inc. | 2026-03-31 | 3/3 | $495,000 | -$17.62M | -$25.28M | -311.7% | -5845.5% | 100 | 尚无授权文本 |
| INDV Indivior Pharmaceuticals, Inc. | 2026-03-31 | 3/3 | $317M | $89M | -$29M | 87.4% | 43.2% | 371 | 尚无授权文本 |
| INM InMed Pharmaceuticals Inc. | 2026-03-31 | 3/3 | — | -$2.97M | — | — | — | 188 | 尚无授权文本 |
| INO INOVIO PHARMACEUTICALS, INC. | 2026-03-31 | 3/3 | $0 | -$19.68M | -$21.59M | — | — | 76 | 尚无授权文本 |
| IRWD IRONWOOD PHARMACEUTICALS INC | 2026-03-31 | 3/3 | $106.51M | $40.77M | — | — | 68.1% | 87 | 尚无授权文本 |
| JAZZ Jazz Pharmaceuticals plc | 2026-03-31 | 3/3 | $1.07B | $293.1M | $388.5M | — | 31.5% | 100 | 尚无授权文本 |
| KNSA Kiniksa Pharmaceuticals International, plc | 2026-03-31 | 3/3 | $214.27M | $22.59M | $50.04M | 90.3% | 13.7% | 80 | 尚无授权文本 |
| KPRX KIORA PHARMACEUTICALS INC | 2026-03-31 | 3/3 | — | -$2.42M | -$3.17M | — | — | 104 | 尚无授权文本 |
| LBRX LB PHARMACEUTICALS INC | 2026-03-31 | 3/3 | — | -$19.05M | -$23.32M | — | — | 16 | 尚无授权文本 |
| LGND LIGAND PHARMACEUTICALS INC | 2026-03-31 | 3/3 | $51.72M | -$13.35M | $48.46M | — | 33.6% | 110 | 尚无授权文本 |
| LUNR Intuitive Machines, Inc. | 2026-03-31 | 3/3 | $183.63M | -$37.39M | -$64.64M | — | -21.3% | 73 | 尚无授权文本 |
| LXRX LEXICON PHARMACEUTICALS, INC. | 2026-03-31 | 3/3 | $21.1M | -$1.04M | — | 99.5% | -4.7% | 101 | 尚无授权文本 |
| MAC MACERICH CO | 2026-03-31 | 3/3 | $241.54M | -$36.35M | — | — | — | 86 | 尚无授权文本 |
| MACI Melar Acquisition Corp. I/Cayman | 2026-03-31 | 3/3 | — | $778,261 | — | — | — | 26 | 尚无授权文本 |
| MACIU Melar Acquisition Corp. I/Cayman | 2026-03-31 | 3/3 | — | $778,261 | — | — | — | 26 | 尚无授权文本 |
| METC Ramaco Resources, Inc. | 2026-03-31 | 3/3 | — | -$18.32M | — | — | — | 141 | 尚无授权文本 |
| METCB Ramaco Resources, Inc. | 2026-03-31 | 3/3 | — | -$18.32M | — | — | — | 141 | 尚无授权文本 |
| METCI Ramaco Resources, Inc. | 2026-03-31 | 3/3 | — | -$18.32M | — | — | — | 141 | 尚无授权文本 |
| METCZ Ramaco Resources, Inc. | 2026-03-31 | 3/3 | — | -$18.32M | — | — | — | 141 | 尚无授权文本 |
| MGNX MACROGENICS INC | 2026-03-31 | 3/3 | $20.78M | -$36.77M | -$36.16M | — | -161.0% | 94 | 尚无授权文本 |
| MIRA MIRA PHARMACEUTICALS, INC. | 2026-03-31 | 3/3 | — | -$1.15M | — | — | — | 80 | 尚无授权文本 |
| MIRM Mirum Pharmaceuticals, Inc. | 2026-03-31 | 3/3 | $159.88M | -$790.16M | -$229.43M | — | -493.8% | 96 | 尚无授权文本 |
| MIST Milestone Pharmaceuticals Inc. | 2026-03-31 | 3/3 | $238,000 | -$26.07M | -$16.1M | 94.1% | -9942.4% | 82 | 尚无授权文本 |
| MKZR MacKenzie Realty Capital, Inc. | 2026-03-31 | 3/3 | $5.44M | -$985,784 | — | — | -46.0% | 109 | 尚无授权文本 |
| MNR MACH NATURAL RESOURCES LP | 2026-03-31 | 3/3 | $285.93M | -$35.04M | — | — | -3.4% | 45 | 尚无授权文本 |
| NRXP NRX Pharmaceuticals, Inc. | 2026-03-31 | 3/3 | $1.07M | -$1.43M | — | 40.9% | -444.0% | 134 | 尚无授权文本 |
| OLMA Olema Pharmaceuticals, Inc. | 2026-03-31 | 3/3 | — | -$53.09M | — | — | — | 84 | 尚无授权文本 |
| ORIC Oric Pharmaceuticals, Inc. | 2026-03-31 | 3/3 | — | -$35.77M | -$32.44M | — | — | 84 | 尚无授权文本 |
| ORMP ORAMED PHARMACEUTICALS INC. | 2026-03-31 | 3/3 | — | $38.31M | -$2.92M | — | — | 104 | 尚无授权文本 |
| PCSA Processa Pharmaceuticals, Inc. | 2026-03-31 | 3/3 | — | -$3.38M | — | — | — | 116 | 尚无授权文本 |
| PFSI PennyMac Financial Services, Inc. | 2026-03-31 | 3/3 | $6.12M | $82.32M | -$1.34B | — | — | 114 | 尚无授权文本 |
| PHIO Phio Pharmaceuticals Corp. | 2026-03-31 | 3/3 | — | -$4M | -$4M | — | — | 114 | 尚无授权文本 |
| PMT PennyMac Mortgage Investment Trust | 2026-03-31 | 3/3 | — | $24.62M | — | — | — | 96 | 尚无授权文本 |
| PMTU PennyMac Mortgage Investment Trust | 2026-03-31 | 3/3 | — | $24.62M | — | — | — | 96 | 尚无授权文本 |
| PMTV PennyMac Mortgage Investment Trust | 2026-03-31 | 3/3 | — | $24.62M | — | — | — | 96 | 尚无授权文本 |
| PMTW PennyMac Mortgage Investment Trust | 2026-03-31 | 3/3 | — | $24.62M | — | — | — | 96 | 尚无授权文本 |
| PMVP PMV Pharmaceuticals, Inc. | 2026-03-31 | 3/3 | — | -$18.04M | -$19.68M | — | — | 65 | 尚无授权文本 |
| QNRX Quoin Pharmaceuticals, Ltd. | 2026-03-31 | 3/3 | — | -$5M | — | — | — | 118 | 尚无授权文本 |
| RARE Ultragenyx Pharmaceutical Inc. | 2026-03-31 | 3/3 | $136M | -$185M | -$198M | — | -124.3% | 119 | 尚无授权文本 |
| RCKT ROCKET PHARMACEUTICALS, INC. | 2026-03-31 | 3/3 | $0 | -$47.59M | -$45.49M | — | — | 97 | 尚无授权文本 |
| RIGL RIGEL PHARMACEUTICALS INC | 2026-03-31 | 3/3 | $58.82M | $8.65M | — | 92.2% | 20.2% | 94 | 尚无授权文本 |
| RXRX RECURSION PHARMACEUTICALS, INC. | 2026-03-31 | 3/3 | $6.47M | -$117.5M | -$81.36M | -93.0% | -1985.6% | 103 | 尚无授权文本 |
| RYTM RHYTHM PHARMACEUTICALS, INC. | 2026-03-31 | 3/3 | $60.11M | -$55.64M | — | 88.1% | -87.1% | 98 | 尚无授权文本 |
| SHPH Shuttle Pharmaceuticals Holdings, Inc. | 2026-03-31 | 3/3 | — | -$2.15M | — | — | — | 109 | 尚无授权文本 |
| SNDX Syndax Pharmaceuticals Inc | 2026-03-31 | 3/3 | $64.86M | -$42.67M | — | — | -52.7% | 91 | 尚无授权文本 |
| SNOA Sonoma Pharmaceuticals, Inc. | 2026-03-31 | 3/3 | $19.53M | -$3.18M | -$4.13M | 38.0% | -12.6% | 89 | 尚无授权文本 |
| SPRY ARS Pharmaceuticals, Inc. | 2026-03-31 | 3/3 | $22.68M | -$60.62M | -$44.95M | — | -265.2% | 87 | 尚无授权文本 |
| SUPN SUPERNUS PHARMACEUTICALS, INC. | 2026-03-31 | 3/3 | $207.71M | -$2.29M | $66.52M | 88.7% | -4.0% | 142 | 尚无授权文本 |
| SXTC China SXT Pharmaceuticals, Inc. | 2026-03-31 | 3/3 | — | -$6.21M | — | — | — | 46 | 尚无授权文本 |
| SXTP 60 DEGREES PHARMACEUTICALS, INC. | 2026-03-31 | 3/3 | $162,092 | -$2.09M | -$2.77M | 47.1% | -1292.5% | 54 | 尚无授权文本 |
| TARS Tarsus Pharmaceuticals, Inc. | 2026-03-31 | 3/3 | $162.05M | -$6.97M | -$30.47M | 94.2% | -3.8% | 89 | 尚无授权文本 |
| TELO Telomir Pharmaceuticals, Inc. | 2026-03-31 | 3/3 | — | -$990,947 | — | — | — | 68 | 尚无授权文本 |
| TNXP Tonix Pharmaceuticals Holding Corp. | 2026-03-31 | 3/3 | $6.88M | -$40.19M | -$44.01M | 77.1% | -603.9% | 393 | 尚无授权文本 |
| UMAC Unusual Machines, Inc. | 2026-03-31 | 3/3 | $8.1M | $10.28M | -$18.11M | 32.8% | -89.7% | 93 | 尚无授权文本 |
| VNDA Vanda Pharmaceuticals Inc. | 2026-03-31 | 3/3 | $51.72M | -$48.57M | -$50.44M | — | -97.1% | 99 | 尚无授权文本 |
| VRCA Verrica Pharmaceuticals Inc. | 2026-03-31 | 3/3 | $5.02M | -$9.68M | — | — | -193.4% | 103 | 尚无授权文本 |
| VRTX VERTEX PHARMACEUTICALS INC / MA | 2026-03-31 | 3/3 | $2.99B | $1.03B | $1.29B | 86.8% | 38.1% | 72 | 尚无授权文本 |
| XENE Xenon Pharmaceuticals Inc. | 2026-03-31 | 3/3 | — | -$102.3M | -$89.03M | — | — | 90 | 尚无授权文本 |
| XFOR X4 Pharmaceuticals, Inc | 2026-03-31 | 3/3 | $2.71M | -$20.24M | — | 77.9% | -749.9% | 123 | 尚无授权文本 |
| ZNTL Zentalis Pharmaceuticals, Inc. | 2026-03-31 | 3/3 | — | -$35.35M | -$32.99M | — | — | 108 | 尚无授权文本 |
| BDRX Biodexa Pharmaceuticals Plc | 2025-12-31 | 2/3 | — | -$6.38M | — | — | — | 141 | 尚无授权文本 |
| EPRX EUPRAXIA PHARMACEUTICALS INC. | 2025-12-31 | 3/3 | $0 | -$38.58M | — | — | — | 84 | 尚无授权文本 |
| GLMD Galmed Pharmaceuticals Ltd. | 2025-12-31 | 3/3 | — | -$10.31M | — | — | — | 125 | 尚无授权文本 |
| TLX Telix Pharmaceuticals Ltd | 2025-12-31 | 2/3 | — | -$7.13M | — | — | — | 57 | 尚无授权文本 |
| UPC Universe Pharmaceuticals INC | 2025-09-30 | 3/3 | $17.86B | -$3.67B | -$5.32B | 35.3% | -16.3% | 52 | 尚无授权文本 |
| TAK TAKEDA PHARMACEUTICAL CO LTD | 2025-03-31 | 2/3 | — | $108.14B | — | — | — | 272 | 尚无授权文本 |
| BMA Macro Bank Inc. | 2024-12-31 | 2/3 | — | $326.49B | — | — | — | 246 | 尚无授权文本 |
| XTLB XTL BIOPHARMACEUTICALS LTD | 2024-12-31 | 2/3 | — | -$1.03M | — | — | — | 75 | 尚无授权文本 |
| MMD NYLI MacKay DefinedTerm Muni Opportunities Fund | — | 0/3 | — | — | — | — | — | 2 | 尚无授权文本 |